EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe

manilatimes.net · 2026-10-15

EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe

TickrTrends take: Johnson & Johnson's involvement in the EXIT-CVD research consortium's launch of clinical studies represents a strategic investment in cardiovascular care innovation across Europe, an area that could generate future revenue streams for the company's pharmaceutical and medical device divisions. Given TickrTrends' current assessment that JNJ is overvalued, investors should monitor whether these research initiatives translate into commercially viable products and market expansion that can justify the company's current valuation premium. The clinical trial phase typically requires years before generating returns, so near-term valuation support from this consortium activity remains uncertain.

Read the full story at manilatimes.net →